|  |
 |
 |
 |
 |
| Predicting the IQ of Future Peopleby Pete Shanks, Biopolitical TimesMay 15th, 2013The resignation of Jason Richwine from the Heritage Foundation raised the profile of racist views about IQ. Expect new publicity soon for genetic claims about intelligence. |
| Direct Action? Seats at the Table? All of the Above?by Pete Shanks, Biopolitical TimesMay 2nd, 2013Last week, some 15 French activists in chimpanzee masks disrupted a Forum on Synthetic Biology in Paris, raising questions about the appropriateness of that kind of activism. |
| Synthetic Biology as Public Relationsby Pete Shanks, Biopolitical TimesApril 17th, 2013Recent synthetic biology projects related to malaria, flu and conservation are providing PR cover for the field and its corporate sponsors. |
| Who Decides What Patients Need to Know?by Pete Shanks, Biopolitical TimesApril 2nd, 2013The American College of Medical Genetics and Genomics report on "incidental findings" in genetic tests has kicked up a storm of controversy, not least because it seems to contradict February's ACMG recommendations about testing children. |
| Cloning, De-extinction, and Possibly Human Applicationsby Pete Shanks, Biopolitical TimesMarch 29th, 2013Synthetic biologist and entrepreneur George Church and cloning expert Robert Lanza are starting a company to change animal reproduction — and maybe human, too, but they wouldn't say that even if it were true. |
| Guidelines for Genetic Testing of Childrenby Pete Shanks, Biopolitical TimesFebruary 28th, 2013A new policy statement from the American Academy of Pediatrics and the American College of Medical Genetics discusses when doctors should suggest a genetic test for a child.
|
| Gene-ism and the Trout in the Milkby Pete Shanks, Biopolitical TimesFebruary 19th, 2013The remains of King Richard III were not really identified by DNA, but that was what the headlines said. |
| Follow the Biotech Money … If You Can Find It by Pete Shanks, Biopolitical TimesJanuary 9th, 2013In a relatively slow period for mergers and acquisitions in genomics and related sectors, Illumina, Amgen, BGI, and BioTime were buyers and 23andMe added financing while Geron sold and Roche held off. |
| Tell the FDA: No Genetically Modified Salmonby Pete Shanks, Biopolitical TimesJanuary 2nd, 2013The FDA released a "Preliminary Finding of No Significant Impact" about a modified Atlantic salmon, but invites comments before a final decision. |
| Biopolitical News of the Year 2012by Pete Shanks, Biopolitical TimesDecember 20th, 2012Artificial gametes and renewed advocacy of inheritable genetic modification are featured in our summary of the news, along with prenatal and other genetic testing, commercial surrogacy, egg freezing, eugenics, DNA databases, stem-cell scandals and more. |
| Top Biopolitical Times posts of 2012by Pete Shanks, Biopolitical TimesDecember 19th, 2012Some of our favorites of the year, including comments on genetic privacy, embryos for sale, April foolery, fraud, eugenics and a whole lot more. |
|
|
 |
 |
 |
 |
| |
|
Highlighted Topics
Pete Shanks, MA, attended Oxford University, where he
studied Philosophy, Politics and Economics, and moved to California in the
mid-1970s. He has been active in a range of local and international political
movements, while mostly making his living in the publishing industry, especially
on the production side; he enjoys the craft of bookmaking. Appalled by the
eugenic possibilities of biotechnology, he has worked with the Center for
Genetics and Society since its earliest days. He is the author of Human
Genetic Engineering: A Guide for Activists, Skeptics, and the Very Perplexed
(Nation Books) and a regular contributor to Biopolitical Times.
